PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Sumanta Kumar Pal, MD, FASCO - RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World Dec 19, 2022

Show notes

Go online to PeerView.com/WYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Robust clinical evidence supports effective upfront treatment platforms based on novel multitargeted tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitor therapies, now standard for patients with renal cell carcinoma (RCC). New options across the disease spectrum allow more patients with metastatic, refractory, or high-risk localized disease to benefit. In PeerView’s latest Clinical Consults video, an expert panel will share their insight for effectively integrating different treatment approaches linked to the latest evidence and expand upon real-life experiences and practical guidance. Upon completion of this activity, participants should be better able to: Evaluate evidence on the role of novel and emerging therapeutics, efficacy, and safety for patients with RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging therapeutic approaches, latest evidence, and patient-, disease- and treatment-specific factors; and Integrate evidence-based strategies and best practices to recognize, mitigate, and manage the unique suite of adverse events associated with novel treatment approaches for patients with RCC

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 1: Why Are We Talking About VTE? Dec 19, 2022

Show notes

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Javed Butler, MD, MPH, MBA - How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure Dec 19, 2022

Show notes

Go online to PeerView.com/EYZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. SGLT2 inhibitors have a newly established role in the foundation of guideline-directed medical therapy for patients with heart failure (HF). As more data has been collected, these agents have evolved beyond their use in diabetes care, with SGLT2 inhibitors now earning a place as vital pharmacotherapy in optimizing the management of patients with HF. Landmark clinical trials of SGLT2 inhibitors have shown clinically relevant and statistically significant reductions in hospitalization for HF events, major adverse cardiovascular events, and kidney events. In this activity based on a recent live symposium, experts review the evidence for using SGLT2 inhibitors in patients with HFrEF, HfpEF, or acute HF, and provide guidance for integrating these multifaceted therapies into cardiology practice using a patient-centered approach. Upon completion of this activity, participants should be better able to: Identify patients with HF who are most likely to benefit from the use of SGLT2 inhibitors; Apply evidence for the use of SGLT2 inhibitors to optimize the management of patients with HF with or without comorbid conditions; and Integrate SGLT2 inhibitors for the treatment of patients with HF, considering indications, dosage, and other clinically relevant characteristics.

David G. Warnock, MD - The Future Looks Bright for People With Fabry Disease: Improving Diagnosis and Expanding Treatment Options Dec 19, 2022

Show notes

Go online to PeerView.com/ZTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert will review the pathophysiology and clinical heterogeneity of Fabry disease. With an emphasis on accurate, early diagnosis and timely treatment, the activity will test learners’ knowledge about current and emerging therapeutic options for patients with Fabry disease. Upon completion of this activity, participants should be better able to: Recognize the pathophysiology, signs and symptoms, clinical manifestations, and consequences of FD; Apply evidence-based tools, technologies, and strategies to diagnose individuals with FD in a timely manner; and Integrate current and emerging options into the treatment regimens, as appropriate, for patients with FD, taking into account the latest efficacy and safety data from recent clinical trials.

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 7: How Should VTE Be Managed in Patients With Obesity? Dec 19, 2022

Show notes

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 2: Tools for Unmasking VTE Quickly Dec 19, 2022

Show notes

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 3: Anticoagulation: When to Use It, With What, and for How Long? Dec 19, 2022

Show notes

Caron Jacobson, MD - Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care Nov 30, 2022

Show notes

Go online to PeerView.com/XZA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This unique video-based activity will offer learners a window into practice by featuring a series of expert-led lectures that will seamlessly link the latest scientific evidence on CAR-T therapy across a range of hematologic malignancies with panel-based insights on clinical decision-making. Each session will include a Tumor Board segment designed to reflect real-world clinical experiences and decision challenges, from identifying patient candidates to appropriate follow-up and the management of a unique spectrum of adverse events. Upon completion of this CE activity, participants will be able to: Evaluate the latest clinical evidence on the safety and efficacy of chimeric antigen receptor (CAR)-T cell therapies in patients with hematological malignancies across existing and potential future indications; Adopt best practices for integrating CAR-T therapy into the care of patients with hematologic malignancies, including appropriate patient selection, referral to specialized treatment centers, clinical trial enrollment, and provision of post-treatment follow-up care; and Develop appropriate adverse event management strategies for patients with hematological malignancies who are experiencing toxicity (eg, cytokine release syndrome or neurotoxicity) while receiving CAR-T therapy.

Daniel J. George, MD - Getting to the Heart of Personalized ADT for Advanced Prostate Cancer: Are You Able to Leverage New Data and Therapy Options to Maximize Cardiovascular Safety and Treatment-Related Outcomes? Nov 30, 2022

Show notes

Go online to PeerView.com/ZYP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This educational program exposes learners to the science that supports the use of GnRH antagonists for appropriate patients with advanced prostate cancer and will enhance their ability to select optimal ADT regimens based on CV risk and other clinically-relevant factors, and optimize CV care and outcomes during ADT. Through a collection of short, focused educational modules, learners will combine self-assessment with concise clinical content in an interactive format. An expert GU oncologist presents digestible self-study segments, with a particular focus on CV considerations associated with ADT approaches. Explore topics pertinent to effective management of patients with prostate cancer on ADT regimens in your clinical practice and learn more about the impact of CV considerations and team-based models of care. Upon completion of this activity, participants should be better able to: Differentiate between GnRH analogues (agonists or antagonists) for patients with advanced prostate cancer with respect to their mechanism of action, clinical effects, cardiovascular (CV) safety, and other attributes; Select patients with advanced prostate cancer who may benefit from treatment with a GnRH antagonist based on CV risk, comorbidities, patient preferences (eg, regarding dosing and/or administration route), and other individualized factors; and Collaborate with multidisciplinary and interprofessional care colleagues to appropriately assess and manage CV risk in patients with advanced prostate cancer who require ADT.

Peter H. Jones, MD, MNLA, R. Scott Wright, MD - Personalizing the Management of Hyperlipidemia: Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel Lipid-Lowering Therapies Nov 30, 2022

Show notes

Go online to PeerView.com/EPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Statin therapy is the cornerstone treatment for dyslipidemia, yet many patients are unable to attain recommended lipid goals with these oral therapies alone. PCSK9-targeting therapies, including monoclonal antibodies and small-interfering RNA, have been shown to reduce LDL-C levels by half, but questions surround the use of these agents and their associated outcomes. In this activity, based on a recent live symposium, leading experts discuss the latest data for these newer targeted therapies and offer evidence-based strategies to better individualize care to improve clinical outcomes, especially in patients with high ASCVD risk. Apply treatment guidelines for the management of hyperlipidemia, for both primary and secondary prevention of cardiovascular events, in patients with ASCVD; Identify the latest clinical evidence, mechanisms of action, and cardiovascular outcomes of approved and emerging non-statin, lipid-lowering therapies, especially PCSK9-targeting agents for managing hyperlipidemia in the ASCVD setting; and Individualize treatment regimens to reduce cardiovascular events in high-risk patients with hyperlipidemia consistent with consensus recommendations and recent clinical evidence available for novel lipid-lowering therapies.